Xenon Pharmaceuticals Inc.

Protiva Biotherapeutics, Inc.

Xenox Pharmaceuticals Inc.

Arbutus Biopharma Corporation

Marcia MacDonald

Yigal Paul Goldberg

Mark E Samuels

Robin Sherrington

Ian MacLachlan

Amy C H Lee

Amy C Lee

The present invention provides compositions comprising therapeutic nucleic acids such as interfering RNA that target apolipoprotein C-III (APOC3) gene expression, lipid particles comprising one or more (e.g., a cocktail) of the therapeutic nucleic acids, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles (e.g., for the treatment of lipid diseases or disorders such as atherosclerosis or a dyslipidemia such as hypertriglyceridemia or hypercholesterolemia).

Compositions and methods for silencing apolipoprotein C-III expression

The present invention relates to the discovery that mutations in SCN9A are causative of Congenital Indifference to Pain (CIP) in humans. The invention also relates to methods of using compounds small organic compounds to treat pain as well as to predict the effect of analgesic agents in patients, such as those possessing gain of function mutations.

Methods for identifying analgesic agents

The present invention relates to the discovery that mutations in SCN9A are causative of Congenital Indifference to Pain (CIP) in humans. The invention also relates to methods of utilizing the SCN9A gene and expression products thereof for the screening and identification of therapeutic agents, including small organic compounds, which are selective for SCN9A, and are useful in the treatment of pain and other disorders. The invention also relates to methods of using these compounds to treat or otherwise ameliorate such disorders.

Methods for treating pain by inhibition of the SCN9A channel

Growing community of inventors

Vancouver, Canada

Marcia MacDonald